Case report: Intranasal esketamine for severe major depressive disorder with psychotic features
Frontiers in Psychiatry July 25, 2022 Maximilian Carter, Kassandra Solsrud, Nicholas Mischel
IntroductionAbout one third of patients with major depressive disorder (MDD) have treatment resistant depression (TRD). The difficulty of treating TRD especially in those with suicidal ideation and psychotic features demands treatments that are fast-acting, safe, and effective. Limited access, lack of viable options, and incomplete characterization of rapid-acting antidepressants has prevented...